Inhibrx Biosciences, Inc. INBX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $25.22M-0.5% | $25.35M-11.2% | $28.54M+28.1% | $22.27M-39.6% | $36.88M+10.5% | ||
| $5.71M+2.4% | $5.57M+5.6% | $5.28M-17.8% | $6.42M+6.6% | $6.02M-63.8% | ||
| $30.93M0.0% | $30.92M-8.5% | $33.81M+17.9% | $28.69M-33.1% | $42.9M-14.2% | ||
| $30.93M0.0% | $30.92M-8.5% | $33.81M+17.9% | $28.69M-33.1% | $42.9M-14.2% | ||
| -$30.93M0.0% | -$30.92M+8.5% | -$33.81M-23.5% | -$27.39M+36.2% | -$42.9M+14.1% | ||
| $3.51M+10.2% | $3.19M+0.1% | $3.18M+1.3% | $3.14M+16.8% | $2.69M— | ||
| -$2.51M-31.6% | -$1.91M-32.3% | -$1.44M-14.3% | -$1.26M-208% | -$410K-120% | ||
| -$33.44M-1.8% | -$32.83M+6.9% | -$35.26M-23.0% | -$28.65M+33.8% | -$43.31M— | ||
| $0— | $0— | $0-100% | $2K— | $0— | ||
| -$33.44M-1.8% | -$32.83M+6.9% | -$35.26M-23.0% | -$28.65M+33.8% | -$43.31M— | ||
| -$2.15-1.9% | -$2.11+7.5% | -$2.28-23.2% | -$1.85+33.9% | -$2.80— | ||
| -$2.15-1.9% | -$2.11+7.5% | -$2.28-23.2% | -$1.85+33.9% | -$2.80— | ||
| 15.6M+0.6% | 15.5M+0.1% | 15.5M+0.1% | 15.5M0.0% | 15.5M+3.2% | ||
| 15.6M+0.6% | 15.5M+0.1% | 15.5M+0.1% | 15.5M0.0% | 15.5M+4.5% | ||
| —— | $1.89M0.0% | $1.89M0.0% | $1.89M0.0% | $1.89M-31.0% | ||
| $1.01M— | —— | $1.78M-16.1% | $2.12M-8.8% | $2.33M— | ||
| -$12K+69.2% | -$39K+15.2% | -$46K+81.3% | -$246K-392% | -$50K-183% | ||
| -$30.93M0.0% | -$30.92M+8.5% | -$33.81M-23.5% | -$27.39M+36.2% | -$42.9M+14.1% | ||
| -$30.39M-0.1% | -$30.36M+8.6% | -$33.23M-24.3% | -$26.73M+36.7% | -$42.23M+14.2% | ||
| -$30.39M-0.1% | -$30.36M+8.6% | -$33.23M-24.3% | -$26.73M+36.7% | -$42.23M+14.2% | ||
| -$30.93M0.0% | -$30.92M+8.5% | -$33.81M-23.5% | -$27.39M+36.2% | -$42.9M+14.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Inhibrx Biosciences, Inc.'s revenue?
- Inhibrx Biosciences, Inc. (INBX) generated $1.3M in revenue over the trailing twelve months, up 550.0% year over year.
- Is Inhibrx Biosciences, Inc. profitable?
- Inhibrx Biosciences, Inc. is not currently profitable: it reported a net loss of $130.2M over the trailing twelve months, a -10773.5% net margin.
- What is Inhibrx Biosciences, Inc.'s earnings per share?
- Inhibrx Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-8.39.
- Where does Inhibrx Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
